Medicaid drug pricing exemption quietly handed to pharma giants

What it does

This bill amends Medicaid drug pricing rules to allow pharmaceutical manufacturers to offer 'value-based purchasing arrangements'—deals where payment is tied to whether patients achieve specific health outcomes—and exempts these arrangements from certain federal pricing and anti-kickback rules. Manufacturers can now report multiple prices for the same drug depending on the outcome achieved, and states can negotiate these outcome-based deals directly with drug makers. The bill benefits pharmaceutical companies by creating pricing flexibility and exempting them from standard rebate calculations, while states gain negotiating options but face complexity in administering these arrangements.

Why we flagged it

The bill's operative mechanism is to exempt value-based purchasing arrangements from standard Medicaid drug rebate calculations and anti-kickback rules, creating pricing flexibility that benefits manufacturers. The framing as 'patient access' and 'outcomes-based' obscures that the primary beneficiary is the pharmaceutical industry, which gains exemptions from price-reporting and rebate obligations.

What the text implies

• The 'multiple best price points' provision allows manufacturers to report different prices for the same drug based on outcome achievement, fragmenting the Medicaid rebate baseline and potentially raising effective prices for non-participating states and patients who don't qualify for outcome-based deals.
• The anti-kickback exception (Section 5) permits manufacturers to pay states when patients 'fail to achieve outcomes'—creating a perverse incentive for states to enroll patients least likely to succeed, shifting financial risk to Medicaid rather than manufacturers.
• The bill requires states to offer the same value-based pricing available in commercial markets, but does not require manufacturers to offer such arrangements at all—giving manufacturers unilateral control over which states and patient populations access outcome-based pricing.
• Installment-payment rules (Section 2) allow manufacturers to defer price recognition across rebate periods, potentially reducing the average manufacturer price calculation and lowering rebate obligations to states and the federal government.
• The GAO study (Section 6) is framed to measure 'access' and 'outcomes' but does not mandate comparison of Medicaid costs under value-based arrangements versus standard rebate-based pricing, leaving the cost-benefit analysis incomplete.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary patients and taxpayers face higher Medicaid drug costs because manufacturers gain pricing flexibility and exemptions from standard rebate rules, while the promised 'value-based' savings are speculative and contingent on manufacturers voluntarily offering better terms. The anti-kickback exception creates a loophole allowing manufacturers to pay states when patients fail to achieve outcomes, which may incentivize states to enroll sicker or less-compliant patients rather than negotiate low

Who stands to gain

• pharmaceutical manufacturers (BMY, PFE, JNJ, GH, DVA)
• specialty drug makers offering rare disease and gene therapies
• manufacturers of inhalation, infusion, and injectable drugs

Named in the bill

BMY (Bristol Myers Squibb), PFE (Pfizer), JNJ (Johnson & Johnson), GH (Gilead Sciences), DVA (DaVita), Department of Health and Human Services, Centers for Medicare & Medicaid Services, State Medicaid agencies, Comptroller General (GAO), Office of Inspector General

Where it stands

17 cosponsors: 11 Republicans, 6 Democrats.

• Mar 9, 2026 — Introduced · Congress.gov: “Introduced in House”
• Mar 9, 2026 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 6 disclosure filings across 2 quarters, Mar 2026 to Jun 2026. Those filings disclosed $4,062,990 in lobbying spend. A filing names 4 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Brett Guthrie, the sponsor, reported $3,193,402 in PAC receipts in the 2026 cycle.

• Pharmaceutical Care Management Association — $3,282,990 on 1 filing
• Orchard Therapeutics North America — $660,000 on 2 filings
• Academy of Managed Care Pharmacy — $80,000 on 1 filing
• Council for Affordable Health Coverage — $30,000 on 1 filing
• Beam Therapeutics — $10,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.